-
学术期刊
-
学术著作
-
精品图书
-
投稿须知
International Medical Research and Translation (IMRT) June 2026, Vol.2, No.3
Progress on Antibody-Drug Conjugates in Solid Tumors
Lianju Wang¹, Xin Li²*
¹School of Clinical Medicine, Qinghai University, Xining, Qinghai 810000, China; ²Affiliated Hospital of Qinghai University, Xining, Qinghai 810000, China
Abstract: Antibody-drug conjugates (ADCs) combine monoclonal antibodies and potent cytotoxic small molecules via specially designed chemical linkers, enabling selective delivery of cytotoxic agents to tumor cells carrying specific surface antigens. Over the last decade, this therapeutic modality has reshaped treatment patterns across numerous solid tumor types. This review first elaborates core ADC working mechanisms, then systematically sorts approved and investigational ADC agents targeting HER2, Trop-2, Nectin-4, CLDN18.2 and other mainstream biomarkers, and summarizes clinical trial evidence covering breast, lung, gastric, urothelial and ovarian malignancies. Multiple landmark ADCs, including trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), domestic disitamab vedotin (RC48) and enfortumab vedotin (EV), have obtained global regulatory approvals and become standard second-line or later-line regimens. Current clinical research further explores their application value in first-line treatment, perioperative intervention and low antigen-expression tumor populations. Nevertheless, acquired drug resistance limits sustained clinical benefit. Novel strategies under exploration, such as bispecific ADC construction, optimized linker chemistry and rational combined treatment schedules, may effectively overcome such therapeutic barriers.
Keywords: antibody-drug conjugates, solid tumors, targeted therapy, HER2, Trop-2, Nectin-4, mechanisms of resistance
